Sinusitis Treatment — EPOS 2020 Evidence-Based Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Rhinosinusitis (RS) — commonly called sinusitis — is inflammation of the mucosa lining the nasal cavity and one or more paranasal sinuses (maxillary, ethmoid, frontal, and sphenoid). It is one of the most prevalent conditions in primary and secondary care, affecting an estimated 10–15% of the adult population in developed countries and accounting for millions of antibiotic prescriptions annually — the majority of which are unnecessary.

EPOS 2020 Classification

The European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS 2020) is the definitive evidence-based guideline used by ear, nose and throat (ENT) specialists internationally. It classifies rhinosinusitis as follows:

• Acute Rhinosinusitis (ARS): Symptom duration less than 12 weeks with complete resolution. Subdivided into:
  • Viral ARS (common cold): Symptoms peak at 2–3 days and improve by 10 days. The vast majority of ARS cases are viral and do not require antibiotics.
  • Post-viral ARS: Symptoms persist or worsen after 5 days following initial improvement — a worsening phase suggesting secondary mucosal changes but not necessarily bacterial superinfection. Intranasal corticosteroids are first-line.
  • Acute Bacterial Rhinosinusitis (ABRS): Bacterial superinfection with at least 3 of: discoloured mucus, severe local pain (unilateral), fever (>38°C), raised CRP/ESR, or "double sickening" (initial improvement then worsening). ABRS accounts for only 0.5–2% of all ARS episodes.
• Chronic Rhinosinusitis (CRS): Symptoms lasting 12 weeks or more, with persistent rhinorrhea, nasal obstruction, facial pain/pressure, or reduction/loss of smell (hyposmia/anosmia), confirmed by nasal endoscopy and/or CT scan. CRS is further categorised as:
  • CRS without nasal polyps (CRSsNP): The more common form; primarily neutrophilic inflammation; often associated with anatomical variants, dental infections, or biofilm-forming bacteria.
  • CRS with nasal polyps (CRSwNP): Eosinophilic type 2 inflammation; bilateral polypoid mucosal swellings arising from the ethmoid sinuses; strongly associated with aspirin-exacerbated respiratory disease (NSAID-ERD), asthma, and atopy.
• Recurrent Acute Rhinosinusitis (RARS): Four or more documented ARS episodes per year with complete symptom resolution between episodes — prompting investigation for underlying predisposing factors.

Understanding this classification is fundamental to selecting the correct treatment: viral ARS requires only symptomatic measures; CRSwNP with eosinophilic inflammation responds to intranasal corticosteroids and biologics; CRSsNP may require surgery for anatomical correction.

Sinusitis encompasses several distinct clinical entities with different underlying mechanisms, risk factors, and treatment pathways:

Viral Acute Rhinosinusitis (Common Cold)

The common cold — caused by rhinovirus (50%), coronavirus, respiratory syncytial virus, adenovirus, and others — is the prototypical viral ARS. It presents with profuse watery rhinorrhea, nasal congestion, sneezing, and mild sinus pressure. Discoloured (yellow-green) mucus after Day 3 reflects neutrophil migration into secretions — it does not indicate bacterial infection. Symptoms peak at 2–3 days and resolve within 10 days without specific treatment.

Acute Bacterial Rhinosinusitis (ABRS)

ABRS is caused predominantly by Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. It develops in a minority of post-viral ARS cases. Diagnostic criteria (EPOS 2020): at least 3 of: discoloured discharge, severe facial pain (unilateral), dental pain, fever, elevated inflammatory markers, or a second worsening phase after initial improvement. Radiological confirmation (CT sinus) is not required for uncomplicated ABRS.

Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

CRSsNP is characterised by neutrophilic inflammation and mucosal thickening without polypoid change. CT sinus shows mucosal thickening, sinus opacification, or osteomeatal complex (OMC) obstruction. Associated with biofilm formation by Staphylococcus aureus, anatomical variants (deviated nasal septum, concha bullosa, Haller cells obstructing the OMC), dental periapical infections (odontogenic sinusitis — especially maxillary sinus), and immune deficiency (IgA, IgG subclass deficiency, primary ciliary dyskinesia).

Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

CRSwNP is the most clinically challenging form. It is driven by type 2 eosinophilic inflammation mediated by IL-4, IL-5, and IL-13 cytokines from innate lymphoid cells type 2 (ILC2) and Th2 lymphocytes. Bilateral nasal polyps arising from the ethmoid labyrinth cause progressive nasal obstruction and smell loss. It is strongly associated with:

• Asthma: Found in 45–60% of CRSwNP patients; polyps worsen asthma control
• Aspirin-exacerbated respiratory disease (NSAID-ERD / Samter's triad): Triad of CRSwNP, asthma, and NSAID hypersensitivity — aspirin and other COX-1 inhibitors trigger bronchospasm. Prevalence: 15–25% of CRSwNP patients.
• Allergic rhinitis and atopy: Present in 40–60% of CRSwNP

Complications of Sinusitis

Serious complications — though uncommon — demand urgent recognition: orbital cellulitis/abscess (periorbital swelling, proptosis, reduced eye movements — ophthalmological emergency), intracranial extension (meningitis, epidural abscess, cavernous sinus thrombosis), and osteomyelitis of the frontal bone (Pott's puffy tumour).

The vast majority of sinusitis episodes are viral, self-limiting, and do not require medical consultation. However, certain clinical features indicate when assessment and treatment are necessary:

Self-Management Is Appropriate When:

• Symptoms began within the last 10 days with a typical cold presentation (profuse clear or coloured mucus, congestion, mild facial discomfort)
• Symptoms are improving progressively (even if slowly)
• There is no fever, no severe unilateral facial pain, and no swelling around the eye
• You are otherwise well with no significant medical comorbidities

Management: saline nasal irrigation, steam inhalation, adequate hydration, paracetamol or ibuprofen for symptomatic relief, decongestants (short-term, maximum 7 days) to reduce nasal congestion.

Consult Your GP When:

• Symptoms persist beyond 10 days without improvement, or worsen after initial improvement ("double sickening")
• Significant unilateral facial pain, dental pain, or fever (>38°C) is present
• There is a history of 4 or more similar episodes in the past year
• Symptoms of chronic rhinosinusitis (nasal obstruction, facial pressure, loss of smell) lasting more than 12 weeks

Seek Emergency Care Immediately When:

• Periorbital (around the eye) redness, swelling, or proptosis (eye pushed forward)
• Double vision or reduced eye movement
• Severe headache that is unusual in character or rapidly worsening
• Neck stiffness, confusion, or photophobia (meningism)
• Forehead swelling (Pott's puffy tumour)
• High fever with systemic toxicity

Referral to ENT Specialist Is Indicated For:

• CRS failing to respond to 12+ weeks of nasal saline irrigation and intranasal corticosteroids (INCSs)
• CRSwNP significantly impairing quality of life
• Unilateral nasal symptoms (single-sided nasal polyp or discharge must exclude malignancy, fungal sinusitis, or CSF rhinorrhoea)
• Recurrent ABRS (≥4 episodes per year)
• Consideration for FESS or biologic therapy (dupilumab)

Sinusitis treatment is stratified by type (viral ARS, ABRS, CRSsNP, CRSwNP) and severity. The following evidence-based options are recommended by EPOS 2020 and NICE guidelines:

1. Intranasal Corticosteroids (INCS) — First-Line for CRS and Post-Viral ARS

INCS are the cornerstone of CRS treatment and have a moderate role in post-viral ARS:

• Mometasone furoate (Nasonex): Strongly recommended for CRSwNP and CRSsNP. In CRSwNP, high-dose mometasone 400 mcg twice daily (licensed dose for nasal polyps in the UK) has demonstrated significant polyp size reduction in multiple RCTs.
• Fluticasone propionate (Flixonase, Avamys): Comparable efficacy to mometasone; available as nasal spray and drops. Fluticasone drops (Flixonase nasule) are used in "head-down, forward-tilt" position to improve delivery to the ethmoid sinuses and are particularly effective for CRSwNP.
• Budesonide, triamcinolone, beclomethasone: Acceptable alternatives; systemic bioavailability is low for all modern INCS at therapeutic doses.

INCS should be used for a minimum of 12 weeks before assessing response in CRS. Regular saline irrigation before application improves mucociliary clearance and steroid delivery.

2. Saline Nasal Irrigation

Isotonic or hypertonic saline irrigation (250–480 mL per side, high-volume low-pressure system — e.g., NeilMed Sinus Rinse) mechanically flushes allergens, biofilm, and inflammatory mediators from the nasal mucosa, improves mucociliary clearance, and reduces the need for medication. Hypertonic saline has a slight advantage over isotonic in symptom reduction. Saline irrigation is safe, inexpensive, and recommended as adjunctive treatment for all CRS subtypes and post-viral ARS.

3. Antibiotics for ABRS — Restricted Use (NICE NG91)

NICE guideline NG91 (2017) and EPOS 2020 recommend a restrictive antibiotic prescribing approach for sinusitis:

• No antibiotic for viral or post-viral ARS (the vast majority of cases)
• No antibiotic for mild ABRS in immunocompetent patients — most resolve spontaneously within 7–10 days
• Antibiotic is appropriate in moderate-to-severe ABRS (all 3 of: bilateral purulent discharge, fever >38°C, and severe pain) OR if the patient is systemically unwell, immunocompromised, or at high risk of complications
• First-choice antibiotic: phenoxymethylpenicillin 500 mg four times daily for 5 days; or amoxicillin 500 mg three times daily for 5 days
• Penicillin allergy: doxycycline or clarithromycin
• Failure after 5 days: co-amoxiclav 500/125 mg three times daily

4. Dupilumab for CRS With Nasal Polyps (Biologic Therapy)

Dupilumab (Dupixent, Sanofi/Regeneron) is a fully human monoclonal antibody targeting the IL-4 receptor alpha subunit, blocking both IL-4 and IL-13 signalling — the key cytokines driving type 2 eosinophilic inflammation in CRSwNP:

• SINUS-24 trial: 276 patients — dupilumab 300 mg subcutaneously every 2 weeks for 24 weeks showed a 51.3% reduction in nasal polyp score (NPS) vs 3.1% placebo; 56.2% improvement in nasal congestion score
• SINUS-52 trial: 448 patients, 52 weeks — dupilumab achieved a 57.3% reduction in NPS, 60.6% improvement in SNOT-22 quality-of-life score, and significantly reduced need for oral corticosteroids and rescue surgery
• NICE recommended dupilumab for CRSwNP refractory to INCS plus surgery (or patients unfit for surgery) in 2021, at a cost-effective threshold
• Dupilumab also improves co-existing asthma and atopic dermatitis — important given the high comorbidity rate

5. Functional Endoscopic Sinus Surgery (FESS)

FESS is the primary surgical treatment for CRS refractory to adequate medical therapy. Performed under general anaesthesia through the nostrils (no external incisions), FESS opens the natural drainage pathways of the sinuses using endoscopes and powered instruments. Key indications:

• CRS failing 12+ weeks of optimal medical therapy (INCS + saline irrigation)
• CRSwNP causing significant obstruction not controlled by INCS or dupilumab
• Suspected complications (orbital or intracranial)
• Aspirin-exacerbated respiratory disease — FESS combined with aspirin desensitisation

Appropriate treatment of sinusitis — matched to the specific type and severity — provides reliable, measurable benefits across multiple symptom domains:

Intranasal Corticosteroids

• Reduce nasal obstruction by 25–40% in CRSwNP at 12 weeks (Cochrane meta-analysis, 2016 — 18 RCTs)
• High-dose mometasone (400 mcg BD) reduces polyp score by 36% at 6 months vs placebo
• Improve olfaction (smell) in 50–60% of CRSwNP patients — a particularly valued benefit given the impact of anosmia on quality of life
• Safe for long-term use — systemic bioavailability of modern nasal steroids is <1%, with no clinically meaningful suppression of the hypothalamic-pituitary-adrenal (HPA) axis at standard doses

Saline Irrigation

< li>Systematic review (Cochrane, 2018) demonstrates moderate-certainty evidence for saline irrigation improving CRS symptoms with minimal harm
• High-volume hypertonic saline achieves greater symptom improvement than low-volume isotonic irrigation
• Reduces reliance on nasal decongestants (which cause rebound congestion with prolonged use)

Dupilumab for CRSwNP

• SINUS-52: 57.3% reduction in nasal polyp score at 52 weeks vs 6.6% for placebo
• 65% of dupilumab patients avoided the need for systemic corticosteroid rescue therapy (vs 27% placebo)
• 57% reduction in need for further sinus surgery in the dupilumab group
• Clinically meaningful improvement in the SNOT-22 quality-of-life score (>8.9 point improvement, vs MCID of 8.9 points)
• Concurrent improvement in asthma control and FEV1 in patients with co-existing asthma — unique biologic benefit across upper and lower airway disease

FESS

• Prospective cohort studies (KRONOS, UK FESS registry) show 74–84% of patients report significant symptom improvement at 12 months following FESS
• SNOT-22 improvement of 30+ points (vs MCID of 8.9) is routinely achieved in successful FESS cases
• FESS for CRSwNP reduces polyp recurrence when combined with post-operative INCS, achieving 50–60% sustained remission at 5 years
• Improved antibiotic penetration into sinuses post-FESS allows more effective management of recurrent ARS

Aspirin Desensitisation (NSAID-ERD)

In patients with aspirin-exacerbated respiratory disease (NSAID-ERD / Samter's triad), FESS combined with aspirin desensitisation protocol (hospital-based, graduated oral aspirin challenge) significantly reduces polyp recurrence rates, improves asthma control, and allows patients to tolerate aspirin and NSAIDs long-term. This specialised approach is available at tertiary rhinology centres.

Different sinusitis treatments carry different risk profiles. Matching treatment to disease severity avoids unnecessary side effects from over-treatment:

Intranasal Corticosteroids — Generally Very Safe

• Local effects: Nasal dryness, epistaxis (nosebleeds, particularly if technique is poor — spray should be directed laterally, not at the nasal septum), and nasal irritation in 5–15% of users
• Systemic effects: Modern INCS (mometasone, fluticasone) have <1% systemic bioavailability. At standard doses (100–200 mcg/day), no clinically significant HPA axis suppression, growth effect in children, or intraocular pressure increase. At very high doses (>400 mcg/day long-term), minor HPA effects possible.
• Nasal septum perforation: Very rare with correct technique. Occurs more commonly with chronic decongestant spray use.

Antibiotics — Risks of Inappropriate Prescribing

• NICE NG91 emphasises that antibiotic prescribing for viral sinusitis provides no clinical benefit but causes antibiotic resistance, Clostridioides difficile (C. diff) diarrhoea, allergic reactions, and disrupts gut microbiome
• Amoxicillin / co-amoxiclav: diarrhoea (10–15%), nausea, rash, allergic reaction (<5%)
• Doxycycline: photosensitivity, oesophageal irritation (take with water, remain upright)

Dupilumab — Biologic Therapy

• Injection-site reactions: Redness, swelling, bruising at the subcutaneous injection site — occurring in 10–15% of patients; generally mild and transient
• Conjunctivitis: Occurs in 5–10% of patients on dupilumab (higher in those with atopic dermatitis). Usually mild blepharoconjunctivitis responsive to topical treatment.
• Eosinophilia: Mild transient blood eosinophil rise in some patients; clinically significant eosinophilic vasculitis (EGPA) has been reported rarely in patients with underlying eosinophilic asthma
• Contraindications: Active parasitic infections (dupilumab reduces eosinophil activity, potentially impairing parasite immunity); pregnancy — category B, insufficient data

FESS — Surgical Risks

• Bleeding: Intraoperative or post-operative epistaxis in 1–5% of cases. Severe haemorrhage requiring re-intervention is rare (<0.5%).
• Orbital complications: Damage to the medial orbital wall (lamina papyracea) can cause orbital fat herniation, periorbital emphysema, or — rarely — orbital haematoma (requiring urgent decompression). Incidence: 0.5–1.5%.
• CSF leak / intracranial complication: Damage to the cribriform plate can cause CSF rhinorrhoea, meningitis, or pneumocephalus. Incidence with experienced surgeons: <0.1%.
• Damage to the nasolacrimal duct: Can cause epiphora (watering eye) — rare with modern endoscopic technique
• Anosmia: Worsening of smell (temporary or permanent) can result from trauma to the olfactory epithelium in the superior nasal cavity — very rare with expert technique

Sinusitis — particularly chronic rhinosinusitis — is a long-term condition requiring ongoing management rather than a single course of treatment. The following outlines the evidence-based follow-up pathway:

Acute Rhinosinusitis

Most viral ARS episodes resolve without follow-up if managed with saline irrigation and symptomatic treatment. Patients should return to their GP if:

• Symptoms do not improve after 10 days (or worsen before 10 days)
• Symptoms suggest ABRS (fever, severe unilateral facial pain, "double sickening")
• Any orbital or intracranial symptoms develop (emergency)

Chronic Rhinosinusitis — Medical Follow-Up

• All CRS patients are initially managed with a 12-week trial of INCS (mometasone or fluticasone) and daily saline irrigation, with GP review at 4 weeks and 12 weeks
• SNOT-22 questionnaire (22-item sinonasal outcome test) is completed at each visit to track symptom severity objectively. A score >20 indicates significant disease burden; MCID is 8.9 points.
• Nasal endoscopy at ENT clinic evaluates endoscopic response (polyp grade, purulent discharge, mucosal oedema)
• CT sinus (low-dose protocol, coronal and axial reconstruction) is performed in CRS failing medical therapy and before surgical planning — not routinely during initial medical management

After FESS — Post-Operative Care

• Immediate post-operative period: Nasal packs (if used) are removed at 24–48 hours. Post-operative bloody nasal discharge is normal for 2–3 weeks. Avoid nose-blowing, strenuous activity, and flying for 2 weeks.
• Nasal debridement: ENT clinic attendance at 1–2 weeks for suction clearance of clot, crusts, and fibrin — essential to prevent stenosis of surgical openings
• Saline irrigation: High-volume saline irrigation begins at 24 hours post-operatively; continued long-term to maintain patency of sinus openings
• INCS restart: Nasal steroid sprays restart at 2–4 weeks post-operatively (once epithelialisation begins); continued indefinitely to prevent polyp recurrence
• ENT follow-up: 6 weeks, 3 months, 6 months, 12 months; annually thereafter for CRSwNP

Dupilumab Follow-Up

Patients on dupilumab are reviewed every 12 weeks. Response assessment uses NPS (nasal polyp score on endoscopy), SNOT-22, and olfactory testing (UPSIT or Sniffin' Sticks). NICE guidance requires a minimum 16-week treatment response assessment before continuing prescription. Dupilumab is continued indefinitely in responders, as polyps typically recur within 3–6 months of discontinuation.

Sinusitis treatment costs range from minimal (self-care with saline irrigation) to significant (biologic therapy with dupilumab). Understanding the cost landscape helps patients and commissioners make informed choices:

Self-Care and Over-the-Counter Treatments

• Saline nasal irrigation kits (NeilMed, NETI pot): GBP 7–15 / USD 10–20 one-off; refill sachets GBP 0.20–0.50 per use
• Intranasal corticosteroid sprays (over-the-counter in UK — mometasone 50 mcg, fluticasone 50 mcg): GBP 6–12 per month; USD 15–30 per month
• Decongestant nasal sprays (oxymetazoline, xylometazoline): GBP 3–5; safe for ≤7 days only
• Paracetamol, ibuprofen: GBP 1–3 per box

Prescription Treatments

• Fluticasone furoate nasal drops (Avamys) or mometasone nasal spray (NHS prescription): GBP 8.60 (NHS prescription charge, 2025); free for exemption-eligible patients
• Antibiotics (5-day course of amoxicillin or phenoxymethylpenicillin): GBP 8–12 on prescription; USD 15–30 in the USA
• Short-course oral prednisolone (5–10 days for acute polyp exacerbation): GBP 1–3 per course

Dupilumab (Biologic Therapy) — High Cost

• List price: approximately USD 36,000–40,000 per year in the USA; GBP 24,000–28,000 per year in the UK before NHS commercial negotiation
• Actual NHS cost (2025): confidential commercial rebate; NICE TA with Patient Access Scheme — available on the NHS at the agreed cost-effective threshold of <GBP 20,000/QALY
• In countries without NHS-equivalent coverage (India, Middle East, Southeast Asia), dupilumab is significantly more expensive. Generic biosimilar dupilumab is anticipated in the late 2020s.
• Private prescription in the UK: approximately GBP 1,800–2,000 per 300 mg injection (fortnightly)

Functional Endoscopic Sinus Surgery (FESS)

• NHS (UK): Performed at no direct cost for eligible patients; included within ENT outpatient and surgical tariffs
• UK private: GBP 4,000–7,500 (unilateral or bilateral FESS, depending on complexity)
• India (JCI-accredited hospitals): USD 1,500–4,000 (excellent surgical training with experienced rhinologists)
• USA: USD 8,000–18,000 (hospital + surgeon fees; insurance usually covers with appropriate pre-authorisation)
• Revision FESS (second operation): 30–40% more expensive than primary surgery

For most patients with CRS, the most cost-effective approach is primary management with high-volume saline irrigation and INCS for at least 12 weeks before escalating to specialist investigation, biologic therapy, or surgery — a strategy that is both clinically evidence-based and resource-efficient.

Beyond standard medical and surgical treatments, a range of alternative, complementary, and lifestyle approaches are used by patients with sinusitis. The evidence base varies considerably between these approaches:

Steam Inhalation

Inhaling steam from a bowl of hot water (with or without eucalyptus, peppermint, or menthol) provides short-term symptomatic relief by moistening inflamed mucosa, temporarily relieving congestion, and promoting mucociliary clearance. The Cochrane review found insufficient RCT evidence to recommend it formally, but it is widely used, safe (when performed carefully to avoid burns), and non-pharmacological.

Decongestants (Short-Term Use Only)

Topical nasal decongestants (oxymetazoline, xylometazoline) rapidly reduce nasal congestion by vasoconstriction of the nasal mucosal blood vessels. They are appropriate for short-term use (≤7 days) in ABRS to facilitate drainage, but must not be used long-term. Use beyond 7 days causes rhinitis medicamentosa (rebound congestion) — a drug-induced worsening of nasal obstruction that becomes self-perpetuating and is very difficult to break without supervised withdrawal.

Antihistamines

Non-sedating antihistamines (cetirizine, loratadine, fexofenadine) are appropriate for patients with CRS associated with allergic rhinitis (a significant comorbidity in 40–60% of CRSwNP patients). They reduce sneezing, watery discharge, and itch in allergic disease but have limited direct effect on sinus inflammation or polyps. Evidence does not support antihistamines as primary sinusitis treatment in non-allergic CRS.

Allergy Testing and Immunotherapy

In patients with confirmed allergic rhinitis as a driving factor for CRS, specific allergen immunotherapy (subcutaneous SCIT or sublingual SLIT) reduces airway sensitivity over 3–5 years and decreases inflammatory burden in the sinonasal mucosa. SLIT for house dust mite (HDM) allergy has a positive NICE quality standard and can reduce polyp burden in CRS patients with concurrent HDM allergy.

Manuka Honey and Herbal Preparations

Manuka honey has in vitro antibacterial activity and has been studied in small pilot trials as a nasal irrigation additive for biofilm-related CRSsNP. Systematic review evidence is insufficient to recommend it as a routine treatment. Herbal preparations (Sinupret, a European phytomedicine containing elderflower, gentian, sorrel, verbena, and cowslip) have modest RCT evidence for symptomatic improvement in viral ARS and are widely used in Germany and Austria.

NSAID Avoidance in NSAID-ERD

For patients with aspirin-exacerbated respiratory disease (Samter's triad), strict avoidance of aspirin, ibuprofen, naproxen, and all COX-1 inhibiting NSAIDs is essential to prevent acute bronchospasm and polyp exacerbation. Paracetamol and highly selective COX-2 inhibitors (celecoxib, etoricoxib at low doses) are generally tolerated but should be introduced under medical supervision.